ArticlePloS one2026
CASP1 as a key autophagy-related gene in atherosclerosis: Identification by bioinformatics analysis and experimental validation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study identified potential autophagy-related genes (ARGs) in atherosclerosis using bioinformatics strategies, aiming to explore novel therapeutic targets for the clinical management of atherosclerosis.
methodsFour gene expression datasets associated with atherosclerosis (GSE100927, GSE43292, GSE28829, and GSE20129) were retrieved from the GEO database of the NCBI and subjected to comprehensive analysis. A list of ARGs was compiled by accessing the HADb. AR-DEGs were screened using the "limma" package in R software. Thereafter, six core genes were identified through the combined application of three machine learning algorithms and PPI network analysis, with subsequent validation conducted using external datasets GSE28829 and GSE20129. Additional analyses included GO annotation, KEGG pathway enrichment, drug prediction, immune infiltration assessment, ceRNA network establishment, and transcription factor (TF) regulatory network analysis. Finally, the expression levels of CASP1 in both in vivo and in vitro models were quantified using WB, RT-qPCR, and IF assays.
resultsA total of 13 AR-DEGs were detected with significant expression differences between the AS group and the control group. After integrative screening via PPI network analysis and machine learning algorithms, followed by validation against external datasets GSE28829 and GSE20129, PRKCD, SERPINA1, CASP1, CXCR4, and CCR2 were confirmed as characteristic biomarkers for AS, and their corresponding microRNAs (miRNAs) were predicted. Immune infiltration analysis indicated that these characteristic genes were correlated with immune cells. Moreover, in vivo and in vitro experimental results demonstrated that CASP1 was highly expressed in AS samples.
conclusionPRKCD, SERPINA1, CASP1, CXCR4, and CCR2 were identified as key genes in atherosclerosis, and their associated ceRNA and TF regulatory networks were predicted. Among these key genes, CASP1 is a promising candidate associated with atherosclerosis and worthy of further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.